INTRODUCTION
The education of natural killer (NK) cells and their response to infection, cancer, and allogeneic tissue are guided by interactions between NK cell receptors and major histocompatibility complex (MHC) class I ligands. These engagements enable NK cells to distinguish diseased cells, which have perturbed expression of MHC class I, from normal healthy cells. Such surveillance by NK cells is achieved with a bipartite system, which combines conserved receptors that recognize nonpolymorphic MHC class I with diverse receptors that recognize polymorphic MHC class I (1).
In humans, polymorphic determinants of human leukocyte antigen-A (HLA-A), HLA-B, and HLA-C are recognized by diverse and rapidly evolving killer cell immunoglobulin-like receptors (KIRs). These bind to the upper face of the HLA class I molecule, making contact with the N-terminal part of the a 1 helix, the C-terminal part of the a 1 helix, and the bound peptide (2) . Key polymorphisms in the a 1 helix determine the three major epitopes recognized by KIR. The C1 epitope of HLA-C is defined by asparagine at position 80, whereas lysine at the same position defines the C2 epitope. In this way, every HLA-C allotype carries either C1 or C2 and is a KIR ligand. By contrast, a minority of HLA-A and HLA-B allotypes are KIR ligands. This function is conferred by a sequence motif at residues 77 to 83, which defines the Bw4 epitope carried by subsets of HLA-A and HLA-B allotypes. Interactions of the C1, C2, and Bw4 epitopes with their cognate KIR are diversified by sequence variation in the KIR, the bound peptide, and other residues of HLA class I that do not directly contact KIR. According to their HLA class I type, individual humans can have one, two, or all three of these epitopes recognized by KIR (3) .
In comparison to the highly diversified interactions of KIR with HLA-A, HLA-B, and HLA-C, the recognition of HLA-E by the CD94/ NKG2A receptor is conserved (2) . HLA-E, CD94, and NKG2A have little polymorphism, and the binding site of HLA-E is specific for peptides corresponding to residues −22 to −14 of the leader sequence of HLA-A, HLA-B, and HLA-C (4, 5). Because HLA-E must bind such a peptide, to properly fold and reach the cell surface, the amount of HLA-E detected by CD94/NKG2A correlates with how much HLA-A, HLA-B, and HLA-C are being made by the cell. This property ensures that CD94/NKG2A + NK cells are sensitive to the overall expression of HLA class I and to its perturbation in cells compromised by stress or disease.
In the nonamer peptides that bind to HLA-E, the anchor residue at position 2 corresponds to residue −21 of the classical HLA class I leader sequence. −21Methionine (−21M), the residue present in all HLA-A and HLA-C allotypes and a minority of HLA-B allotypes, provides a good anchor residue that facilitates the folding and cell surface expression of HLA-E (6). In contrast, −21threonine (−21T), the residue present in most of the HLA-B allotypes, does not bind effectively to HLA-E. The dimorphism at position −21 of the HLA-B leader sequence has been correlated with susceptibility to HIV infection (7) and with capacity for NK cell-mediated killing of HIVinfected cells (8) .
In reviewing the effects of NKG2A and HLA-E on HIV infection, Yunis et al. (9) noted that there is a strong tendency for Bw4 + HLA-B to have −21T. One implication of this bias is that disease correlations made with Bw4 (10) could be due to either the direct interaction of the Bw4 epitope with cognate KIR or the indirect effect that a reduced supply of HLA-E binding peptide has on CD94/NKG2A recognition of HLA-E. A second implication is that Bw4 CD94/NKG2A ligands than the Bw4 − HLA-B allotypes that do not function as KIR ligands. To explore these implications, we investigated whether such genetic and functional segregation is a more general principle in the human system of NK cell receptors and MHC class I ligands.
RESULTS

C2
+ HLA-C and −21M HLA-B segregate on different HLA haplotypes in Eurasian populations Comparison of 16,384 HLA haplotypes, representing 51 anthropologically well-defined human populations worldwide ( fig. S1 ), shows that HLA haplotypes encoding C2
+ HLA-C almost always encode −21T HLA-B. Thus, 92.6% of the 5439 haplotypes encoding C2 + HLA-C also encode −21T HLA-B, whereas only 7.4% of the haplotypes combine C2
+ HLA-C with −21M HLA-B. In contrast, the 10,945 haplotypes encoding C1 + HLA-C exhibit a more even distribution of the −21T (68.6%) and −21M (31.4%) forms of HLA-B leader peptide (Fig. 1A) . These results show that C2, a stronger KIR ligand than C1, is usually paired with forms of HLA-B that are unable to contribute peptides that bind HLA-E and form CD94/NKG2A ligands. This bias points to persisting selection against haplotypes that contribute both a C2 ligand for KIR and an HLA-E ligand for CD94/NKG2A.
Dimorphism at position −21 of HLA-B modulates the supply of CD94/NKG2A ligands, whereas dimorphism at position 80 of HLA-C determines the presence and abundance of C1 and C2 ligands. Together, the two dimorphisms define four different haplotypes. The haplotype frequencies were used to calculate D′, a measure of linkage disequilibrium (LD), for each population. This analysis revealed a marked difference between African and nonAfrican populations. Seven African populations exhibit no LD between −21 HLA-B and 80 HLA-C, whereas 27 of the 44 non-African populations exhibit complete LD (D′ = 1) and 8 others have D′ ≥ 0.9 (Fig. 1B) . All populations of European origin have high D′, as do 16 of the 23 Asian populations. In Eurasian populations, there is an effective exclusion of −21M HLA-B from haplotypes encoding the C2 epitope, whereas Africans have no such exclusion.
Seven Asian populations with D′ < 0.9 ( Fig. 1B) have particularly high frequencies of −21T HLA-B and C1
+ HLA-C (N80), an imbalance that reduces the robustness of the D′ calculation. Although these populations have low frequencies of C2 + HLA-C haplotypes, in absolute number, they have many of these haplotypes, and most of them (90.2%) encode −21T HLA-B. We can therefore conclude with confidence that haplotypes combining −21M HLA-B and C2 + HLA-C are rare in all Eurasian populations.
Worldwide, we found only five different HLA haplotypes that combine −21M HLA-B with C2 + HLA-C ( fig. S1 ). These three African and two Asian haplotypes form three groups. Group I comprises two common African haplotypes that have African-specific HLA-B and HLA-C alleles: B*42:01-C*17:01 and B*81:01-C*18:01 (Fig. 1C) . Distinguishing HLA-C*17, HLA-C*18, and HLA-C*07 from other HLA-C allotypes is alanine at position −17 in the leader peptide. For HLA-C*07:01, this residue prevents production of a peptide that binds and stabilizes HLA-E (11, 12) . Group II is represented by the third African haplotype, which combines African-specific HLA-B*81:01 with globally widespread HLA-C*04:01 (Fig. 1C) . Peptides derived from the HLA-B*81:01 leader sequence are predicted to promote surface expression of HLA-E.
Group III comprises two Asian haplotypes. Both are rare and combine HLA-C*15:05 with either HLA-B*73:01 or HLA-B*07:05 (Fig. 1C) . Modern humans acquired the B*73:01-C*15:05 haplotype, by introgression in Asia from archaic humans (13) . HLA-B*73:01 is an unusual HLA-B allotype that carries the C1 epitope (14) . Consequently, the B*73:01-C*15:05 haplotype supplies both the C1 (B*73:01) and C2 (C*15:05) epitopes. HLA haplotypes that combine C2 + HLA-C with −21M HLA-B are rare in Eurasia and could all have derived from a single event of archaic introgression. Haplotypes combining C2
+ HLA-C and −21M HLA-B are more common in Africa but mainly involve African-specific HLA-C allotypes having leader sequences that poorly promote HLA-E expression.
In cells and individuals, HLA haplotypes do not function alone but in diploid combinations: genotypes. Of 8192 individuals in the 51 populations, 6.1% are −21M HLA-B homozygotes (M/M), 31.6% are −21M/−21T heterozygotes (M/T), and 62.3% are −21T HLA-B homozygotes (T/T) (Fig. 1D) . Thus, a large majority of human individuals (93.9%) have −21T HLA-B, whereas a minority (37.7%) have −21M HLA-B. Although differing in their relative frequencies, −21M and −21T HLA-B are both present in all human populations. The frequency of the minor allele −21M HLA-B is highest in Europe, lowest in Australia, and at intermediate levels in Asia, Africa, America, and Polynesia. In populations with higher frequencies of −21M HLA-B, there is complete segregation of −21M HLA-B and C2 + HLA-C onto different subsets of HLA haplotypes.
−21M MHC-B is the ancestral form from which −21T MHC-B was derived
The fact that all HLA-A and HLA-C and some HLA-B have −21M suggests that −21M was the ancestral form of the leader sequence from which −21T was derived. To test this hypothesis, we examined MHC class I leader sequences of apes and Old World monkeys, the species most related to humans (15) . , and none has −21M. Thus, the trend for −21T to replace −21M at HLA-B has gone to near completion at Patr-B. Whereas −21M is fixed at HLA-C, replacement of −21M by −21T is seen in 5 of 22 Patr-C allotypes. All these patterns of substitution are consistent with −21T having derived from −21M in a common human-chimpanzee ancestor.
Only one point mutation can convert −21M to −21T. This is replacement of "T" in methionine codon ATG with "C" to give threonine codon ACG. In addition to methionine, only five other residues-threonine, arginine, isoleucine, leucine, and valine-are present at position −21 in primate MHC-A, MHC-B, and MHC-C ( fig. S2 ). Each of these residues is specified by a codon that can be formed by point mutation of the methionine codon. In contrast, no other codon present at position −21 (threonine, arginine, isoleucine, leucine, or valine) can give rise to all the other codons by point mutation ( fig. S3 ). These various lines of evidence make it almost certain that methionine was the ancestral residue at position −21 of primate MHC-A, MHC-B, and MHC-C. This subset of HLA haplotypes encodes HLA-B that promotes the expression of HLA-E, the CD94/NKG2A ligand, and C1 + HLA-C, the ligand for KIR2DL2/3. On the other hand, the subset of HLA haplotypes that have −21T HLA-B can provide the Bw4, C2, and C1 ligands for KIR3DL1, KIR2DL1/S1, and KIR2DL2/3, respectively, but cannot supply peptides derived from the HLA-B leader sequence that promotes the formation of HLA-E ligands for CD94/NKG2A. Thus, dimorphism at position −21 in the HLA-B leader peptide is seen to divide HLA haplotypes into two functional groups: one is biased toward the supply of CD94/NKG2A ligands, and the other is biased toward the supply of KIR ligands. The goal of subsequent experiments was to test this hypothesis with analyses of immunological function. Fig. 2A) , and individuals of all three −21 HLA-B genotypes are included in the groups of donors defined by the HLA-E genotype. Thus, the HLA-E genotype is not a major cause of the expression differences between the M/M, M/T, and T/T donors. In addition, examining the 1000 Genomes database of wholeexome sequences for 2352 individuals found no evidence for LD between alleles of HLA-E and −21 HLA-B.
A second functional effect of increasing −21M copy number is to decrease the frequency of NK cells that express CD94/NKG2A ( Fig. 2B and fig. S8 ). Again, the big difference is between donors who lack −21M (T/T) and donors who have −21M (M/M plus M/T) (R 2 = 0.44, P = 1.5 × 10 −10 ), with M/M donors exhibiting a small decrease in the additional CD94/NKG2A + NK cell number from that seen for M/T donors. A third effect of higher −21M copy number is to reduce the amount of CD94/NKG2A expressed at the NK cell surface (R 2 = 0.5, P = 5 × 10 −10 ) ( ) is shown with a two-tailed P value. All donors were CMV-negative.
and T/T genotypes. With population frequencies of 31.6 and 62.3%, respectively, the M/T and T/T donors comprise a large majority (93.9%) of the human species. That decreased frequency of CD94/ NKG2A + NK cells, with decreased surface expression of CD94/ NKG2A, correlates with −21M copy number suggests that these effects are caused by increased supply of HLA-E binding peptides. S6 ). This weakly expressed allele is subject to microRNA-148a (miR-148a)-mediated down-regulation (22) . Other HLA-C alleles expressed by M/M donors, HLA-C*08 and HLA-C*12, are not affected by miR148a and exhibit higher expression. Only one M/M donor is homozygous for higher-expressing HLA-C alleles. The cluster of 20 data points ( Fig. 3B ) comprises three phenotypic subclusters corresponding to three genotypes: 12 HLA-C*07 homozygotes with extremely low expression, 7 HLA-C*07 heterozygotes with very low expression, and 1 HLA-C*08 homozygote with low expression. The levels of HLA-C expression we observe are consistent with known differences in the properties of HLA-C alleles ( fig. S6 ). HLA-C*07 is on a characteristic European haplotype, in which the linked −21M HLA-B allele is either HLA-B*07 or HLA-B*08. Both haplotypes have characteristics suggestive of Neanderthal origin (13) .
Within the T/T donor cohort, HLA-C expression varies widely, forming clusters of data points at high, low, and intermediate values (Fig. 3A) . M/T donors have HLA-C levels that span the range from low to intermediate of the T/T donors. The difference between M/M and T/T donors is striking (P = 0.0008, MannWhitney test; n = 40), and that between M/M and M/T donors is significant (P = 0.002, Mann-Whitney test; n = 40). The data points obtained for M/T donors form two clusters, corresponding to the intermediate and low clusters of T/T donors (Fig. 3A) . The three clusters of HLA-C expression correlate with polymorphism at position 80 and its phenotypic expression as C1 and C2 epitopes. The low-level cluster is enriched with C1/C1 homozygotes and includes all M/M donors. The high-level cluster is enriched with C2/C2 homozygotes, which are all T/T donors. The intermediate-level cluster is enriched with C1/C2 heterozygotes (Fig. 3C) .
A dimorphism that markedly affects HLA-C expression is in the miR-148a binding site of the 3′ untranslated region (22) . Transcription is lower for HLA-C alleles with intact miR-148a binding sites but higher for alleles that acquired a nucleotide deletion in the binding site (Fig. 3D) . In HLA-C, there is LD between codon 80 encoding C2 and the deleted form of the miR-148a binding site. They are also in LD with −21T of HLA-B. This extended LD explains the similar patterns observed in Fig. 3 (A to D) . This shows how HLA-B and HLA-C dimorphisms act in concert to modulate HLA-C expression.
Dimorphism at position −21 of HLA-B divides the human population into three subpopulations (M/M, M/T, and T/T) that have distinctive patterns of HLA-C expression (Fig. 3E, F and G) . Restricted to C1
+ HLA-C, M/M donors have low HLA-C expression [<100 median signal intensity (msi)] and genotypes dominated by HLA-C*07 (Fig. 3E) . For the 12 HLA-C*07 homozygotes and 23 heterozygotes, the mean surface expression is 40 and 60 msi, respectively. (Fig. 3 , E to G) demonstrate that HLA-C*07 has the lowest expression and also suggest that, in heterozygotes, HLA-C*07 can suppress the expression of other HLA-C alleles. M/T donors (Fig. 3F ) exhibit more variety in HLA-C genotype and wider range of surface expression (<200 msi) than M/M donors (Fig. 3E) . M/T donors with higher HLA-C expression (100 to 200 msi) than M/M donors typically have HLA-C alleles that are unaffected by miR-148a (Fig. 3F) . Nonetheless, the dominant effect of HLA-C*07 is still observed for M/T donors. This is not so for T/T donors, with their greater variety of HLA-C genotypes and expanded range (<300 msi) of surface expression (Fig.  3G) . The cluster of high-expressing individuals comprises four C2 + HLA-C homozygotes, a genotype specific to T/T donors, and two C1 + HLA-C homozygotes ( fig. S6 ).
−21M HLA-B increases phenotypic diversity in the population of CD94/NKG2A + NK cells Because −21M HLA-B acts to decrease the size of the CD94/NKG2A + NK cell population (Fig. 2) , we further investigated this subset of NK cells. For PBMCs of 60 donors, the expression of 35 cell surface markers (table S1) was analyzed by mass cytometry. These data were subjected to hierarchical clustering analysis using spanning-tree progression analysis of density-normalized events (SPADE) (Fig. 4) (23, 24) . Within the donor panel, the diversity of CD94/ NKG2A + NK cells is considerable: Individuals have 337 to 989 different phenotypes. In general, the CD94/NKG2A + NK cells of M/M donors have greater phenotypic diversity than those of T/T donors (P = 2 × 10 , Mann-Whitney test; n = 40) (Fig. 4A) . M/T donors have the highest phenotypic diversity, but their differences with M/M donors did not reach statistical significance. This analysis shows how −21M HLA-B has two important effects: reducing the size of the (table S1) .
CD94/NKG2A + NK cell population and increasing its phenotypic diversity.
−21M HLA-B copy number also influences the expression of other inhibitory receptors by CD94/NKG2A + NK cells. The frequencies of CD94/NKG2A + NK cells expressing one or more of KIR2DL1 (Fig. 4B), KIR3DL1 (Fig. 4C) , KIR3DL2 (Fig. 4D), and LILRB1 (Fig.  4E) are highest in M/M donors, lowest in T/T donors, and intermediate in M/T donors. Because M/M donors lack Bw4 and C2 ligands, these data (Fig. 4) show that CD94/NKG2A + NK cells most frequently coexpress KIR2DL1 and KIR3DL1 in the absence of their ligands. In T/T donors that have C2, or Bw4, the frequencies of CD94/NKG2A + NK cells expressing the C2-specific KIR2DL1, or Bw4-specific KIR3DL1, are much reduced. During development and education, the acquisition of a self-reactive KIR by CD94/NKG2A + NK cells usually leads to down-regulation and loss of surface CD94/NKG2A (25, 26) .
SPADE analysis shows that −21M copy number correlates with increasing numbers of CD57-expressing CD94/ NKG2A + NK cells (Fig. 5A ). Qualitative differences were also observed. M/M and M/T donors exhibit comparable CD57 expression by their subsets of CD94/ NKG2A + NK cells expressing KIR2DL1, KIR3DL1, KIR3DL2, and LILRB1. The pattern is different for T/T donors, where CD57 is expressed by fewer subsets of CD94/NKG2A + NK cells. These subsets express KIR3DL2 and LILRB1, but little KIR2DL1 or KIR3DL1. Consistent with CD57 being characteristic of educated NK cells (27, 28) , components of activating pathways-CD16, CD122, NKG2D, and 2B4-are expressed at significantly higher frequencies by CD57 + CD94/NKG2A + NK cells compared with CD57 − CD94/ NKG2A + NK cells (Fig. 5, B to G).
−21M HLA-B correlates with functionally stronger CD94/NKG2A + NK cells Phenotypic analysis points to the small, diverse populations of CD94/NKG2A + NK cells of M/M and M/T donors being better educated and functionally more potent than the large but less diverse populations present in T/T donors. This hypothesis was tested using three assays of NK cell function. The first assay compared the capacity of CD3 − CD56 dim NK cells from M/M, M/T, and T/T donors to mediate antibody-dependent cellular cytotoxicity (ADCC) (Fig. 6A) . NK cells were challenged with Raji cells coated with anti-CD20 and assessed for cytotoxic activity, as measured by surface expression of CD107a. At antibody concentrations of 1.25 to 2.5 mg/ml, NK cells from M/M donors made stronger, more sensitive ADCC responses than NK cells from T/T donors, with NK cells from M/T donors exhibiting intermediate responses (Fig. 6A) .
The second assay assessed the interferon-g (IFN-g) response of NK cells activated by a fixed concentration of interleukin-12 (IL-12) (10 IU/ml) combined with different concentrations of IL-15 (Fig. 6B) . At low IL-15 concentrations (0.001 to 1 ng/ml), NK cells from M/M donors produced more IFN-g than those from T/T donors (P = 0.002, 
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Mann-Whitney test; n = 40), with NK cells from M/T donors giving intermediate responses. At higher IL-15 concentrations, the trend was similar but not statistically significant. The third assay compared the missing-self response of NK cells from M/M, M/T, and T/T donors (Fig. 6, C and D) . PBMCs, cultured overnight with IL-12 and IL-15, were then challenged with MHC class I-deficient K562 target cells. In assays of degranulation (Fig. 6C) and IFN-g production (Fig. 6D) , NK cells from M/M and M/T donors responded more effectively than those from T/T donors. Correlating with these differences is an abundance of CD122 on the CD94/NKG2A + NK cell surface (Fig. 5C) . In all three functional assays, the sensitivity and potency of the NK cell response correlate with the presence of −21M HLA-B.
−21M HLA-B correlates with better educated CD94/NKG2A + NK cells To examine how −21 HLA-B dimorphism influences NK cell education, ADCC assays were performed and the NK cells responding with IFN-g or cytotoxicity (cell surface CD107a) were analyzed using mass cytometry and Boolean gating ( fig. S9 ). CD57 expression was used to distinguish educated NK cells that are differentiated from those that are undifferentiated. Comparison of M/M, M/T, and T/T donors identified significant differences in the size of several NK cell subsets, effects that differed between the cytokineproducing NK cells and the cytotoxic NK cells (Fig. 7A) .
The NK cells that can only be educated by the inhibitory HLA-E receptor CD94/NKG2A are the subset of KIR − CD94/NKG2A + NK cells. The subset of KIR − CD94/NKG2A + cells that produce IFN-g in the ADCC assay is of similar size in M/M (33.3% of total NK cells), M/T (31.5%), and T/T (34.4%) donors (Fig. 7B) . However, the extent to which these educated cells are differentiated (CD57 effects of −21 HLA-B dimorphism on cytotoxic NK cells are qualitatively different and quantitatively weaker than those observed for cytokine-producing NK cells. These differences are reflected in the comparisons of Fig. 7A . For CD107a expression, the significant correlations are seen only for NK cells expressing both KIR and CD94/NKG2A, cells for which the educating receptor is unknown. In contrast, for the IFN-g-producing NK cells, significant correlations were made for NK cells expressing only CD94/NKG2A or only KIR, and for which the educating receptor is defined.
−21 HLA-B dimorphism shapes the inhibitory NK cell receptor repertoire For each donor, we determined the frequency of CD56 dim NK cells that express KIR2DL1, the inhibitory C2-specific receptor. For the three donor groups, we see similarly wide frequency ranges and similar mean frequencies (Fig. 8A) − donors. Applying the same analysis to KIR2DL2/3, the inhibitory C1-specific receptor gave similarly wide frequency ranges for KIR2DL2/3 + NK cells and comparable mean frequencies for the three donor groups (Fig. 8B) . Because of the high C1 frequency, an educating effect could only be assessed for T/T donors. In the presence of C1, the mean frequency of KIR2DL2/3 + NK cells was 18.9%, compared with 13.3% in its absence. Thus, the presence of an educating C1 or C2 ligand increases the proportion of NK cells expressing the cognate KIR (29) .
Within the CD56 dim NK cell population, the combinatorial patterns of expression for six inhibitory HLA class I receptors (KIR2DL1, KIR2DL2/3, KIR3DL1, KIR3DL2, CD94/NKG2A, and LILRB1) were determined by mass cytometry and Boolean gating analysis (Fig. 8C and fig. S10 ). Of 64 possible phenotypes, 38 were present in all donors. Thirty-four of these phenotypes each account for >1% of the CD56 dim NK cells. The null phenotype that has no inhibitory receptors has the highest frequency (mean, 7.3%; 60 donors). The other 33 common phenotypes have between one and three inhibitory receptors. Thus, phenotypes comprising four or more inhibitory receptors are rare.
Comparison of the inhibitory receptor repertoires for the M/M and T/T donors identified four phenotypes that are significantly more abundant in M/M donors (P = 0.0001, Mann-Whitney test; n = 40). These phenotypes, which are at low frequency in M/M donors and absent from T/T donors, combine either four or five inhibitory receptors (Fig. 8C ). NK cells with these phenotypes are also present in M/T donors. Six phenotypes are significantly more abundant in T/T donors (P = 0.00005, Mann-Whitney test; n = 40). These six phenotypes are well represented in M/M and T/T donors but have higher frequencies, comparable to the null phenotype frequency, in T/T donors. Of the six phenotypes, two comprise one receptor: CD94/ NKG2A alone and KIR3DL1 alone. Common to the other four phenotypes is CD94/NKG2A, which is paired in turn with each of the four inhibitory KIRs. The increased abundance of NK cells having these six phenotypes is largely responsible for T/T donors having larger CD94/NKG2A + NK cell populations than M/M donors. The striking differences between the NK cell subpopulations that are elevated in M/M and T/T donors reflect the mature, well-educated NK cells of the former and the immature, less educated NK cells of the latter.
DISCUSSION
Two structurally unrelated and functionally complementary forms of inhibitory HLA class I receptor shape the education and function of human NK cells (30, 31) . The older and more conserved receptor, CD94/NKG2A, recognizes the complex of HLA-E and a nonamer peptide cleaved from the leader sequence of HLA-A, HLA-B, or HLA-C (4, 5). A corresponding CD94/NKG2A receptor is present in mice, which recognizes the complex of Qa1 and a nonamer peptide cleaved from the leader sequences of polymorphic H2 polypeptides (32) . More recently evolved than CD94/ NKG2A are the highly diversified KIRs, which recognize conformational determinants of HLA-A, HLA-B, and HLA-C (the Bw4, C1, and C2 epitopes) and are present only in higher primates (33) . Thus, the KIR system of receptors and MHC class I ligands emerged and evolved within the context of an established system of CD94/NKG2A receptors that had been in place for more than 90 million years. In this setting, the epitopes recognized by KIR evolved in a stepwise fashion over a period of 40 million years: first, the Bw4 epitope; then, the C1 epitope; and most recently, the C2 epitope (33) . By combining worldwide genetic analysis of human populations with phylogenetic comparison and functional analysis, our study demonstrates how stepwise addition of each KIR ligand was accompanied by changes and adaptation in the way that NK cell education and response are mediated by CD94/NKG2A recognition of HLA-E.
The nonamer peptides that bind HLA-E have methionine at position 2, which corresponds to position −21 in the MHC class I leader sequence. Before emergence of the KIR gene family, and during its early expansion, −21M was fixed in the leader sequences of polymorphic MHC class I. That is still true for HLA-A and HLA-C, but not HLA-B. In~80% of HLA-B allotypes, −21M was replaced by threonine, which does not promote surface expression and recognition of HLA-E by CD94/NKG2A. Because of this functional dimorphism, HLA-B is predicted to make variable contributions to the pool of HLA-E binding peptides, whereas HLA-A and HLA-C are not. We show here that surface expression of HLA-E is reduced by 16% in homozygous −21T HLA-B individuals compared with homozygous −21M HLA-B individuals. Although modest in magnitude, we find that this effect has considerable impact on the education and function of human NK cells.
A striking bias is that 11 of 12 groups of Bw4 + HLA-B allotypes have −21T, whereas the groups of Bw4 − HLA-B allotypes more evenly divide into ones having −21M and −21T. This LD, between functional dimorphisms of the leader peptide and the a 1 domain of HLA-B, is consistent with there being selection against HLA-B allotypes that contribute to both CD94/NKG2A and KIR ligands.
Like Bw4 + HLA-B, C2 + HLA-C is rarely present on haplotypes having −21M HLA-B. Although such haplotypes have C1 + HLA-C and a potential for C1-mediated NK cell education, it is reduced because their HLA-C alleles are subject to miR-148a-mediated transcriptional down-regulation. Thus, there is LD between −21M/T HLA-B dimorphism and dimorphism in the HLA-C 3′ untranslated region, which determines which HLA-C alleles are affected by miR-148a. The net effect is that −21M HLA-B haplotypes encode HLA-C that has lower cell surface expression than HLA-C encoded by −21T HLA-B haplotypes.
Our population genetic and phylogenetic analyses identified two qualitatively different groups of HLA class I haplotype. Although defined by the simple methionine/threonine dimorphism at position −21 in the leader peptide, this dimorphism has had a profound impact on the evolution of the HLA complex and of human NK cell diversity. The subset of HLA haplotypes defined by −21M HLA-B increases cell surface expression of HLA-E and its capacity to mediate NK cell education and effector function through interaction with CD94/NKG2A. In contrast, the group of HLA haplotypes defined by −21T decreases expression and functional potential of HLA-E but increases the frequency and surface expression of the Bw4, C1, and C2 ligands and their potential to mediate NK cell education and effector function through engagement of KIR. The dimorphism at position −21 of HLA-B defines three groups of individuals-M/M homozygotes, M/T heterozygotes, and T/T homozygotes-that comprise about 6, 32, and 62% of the human population, respectively. Each group exhibits functional differences, but the effect of −21M is so dominant that M/M and M/T individuals are similar, whereas T/T is different from both of them. We will therefore focus on the comparison of M/M with T/T homozygotes.
M/M donors lack the Bw4 and C2 epitopes and, in general, have a more restricted set of HLA types than T/T donors. Their cells express low levels of C1 + HLA-C and high levels of HLA-E. Education through HLA-E produces a phenotypically diverse population of CD94/NKG2A + NK cells that express markers of activation, differentiation, and education, such as CD16 and CD57. These NK cells are effective in mediating ADCC, in secreting cytokines, and in killing HLA class I-deficient cells with a "missing-self" response; they are also responsive to cytokines, such as IL-15.
With (34) . By binding to CCR5, MIP-1b prevents HIV from engaging its co-receptor, which inhibits both the progress and spread of infection (35) . These observations suggest that CD94/NKG2A + NK cells of T/T donors could be more effective in responding to some types of infection, like HIV, than the more educated CD94/NKG2A + NK cells of M/M donors. Consistent with this thesis are the results from a study of heterosexual couples in which one partner is HIV-infected and the other is not, despite exposure to the virus. Uninfected partners of T/T genotype were more resistant to infection than the uninfected partners of either M/T or M/M genotype. Moreover, the NKG2A + NK cells from uninfected T/T partners were more effective at killing autologous HIV-infected target cells in vitro than the NKG2A + NK cells of uninfected M/T or M/M partners (7, 8) . Here, the effect of −21M is dominant and −21T is subordinate, the hierarchy observed throughout our analysis.
The characteristic CD56 dim CD94/NKG2A + NK cells of T/T donors are also implicated in controlling HIV viremia and providing protection from AIDS. These beneficial effects were first correlated with homozygosity for Bw4 + HLA-B (10). Subsequent appreciation that Bw4 correlates with −21T HLA-B led to a reanalysis of the clinical data that showed that the beneficial effects correlate well with −21T HLA-B homozygosity (9) . Thus, the correlation with Bw4 homozygosity can also be interpreted in terms of a mechanism involving HLA-E recognition by the CD56 dim CD94/NKG2A + cells of T/T donors, NK cells known to be effective against HIV (7, 8) . Thus, the protection associated with Bw4 + HLA-B homozygosity could be mediated by KIR3DL1 + cells or CD94/NKG2A + cells, or by their combination. Similarly, because C2
+ HLA-C is also in LD with −21T, disease associations with C2
+ HLA-C could be mediated by direct interaction of the C2 epitope with the KIR2DL1 or KIR2DS1 NK cell receptors, by the effect of −21T HLA-B on HLA-E and CD94/NKG2A + NK cells, or by some combination of the three ligand-receptor interactions.
There are limitations to our study. The donor panel was not large in size, and particular HLA class I alleles and haplotypes of European origin are highly represented. We did not type the KIR genes of the donor panel. There are known differences in cell surface expression levels and in the strength of signaling associated with specific KIR alleles. Neither did we perform any studies to correlate the −21M/T HLA-B dimorphism with disease.
Here, we have shown how two groups of HLA-B and HLA-C haplotypes provide different schools of human NK cell education. The ancestral haplotype encodes −21M HLA-B and C1 and promotes NK cell education by CD94/NKG2A. In contrast, the younger haplotypes encode −21T HLA-B, in various combinations with Bw4, C1, and C2, and promote NK cell education mediated by KIR. The balance between the two groups of HLA-B and HLA-C haplotypes provides heterozygotes with a greater NK cell diversity compared with either homozygote.
MATERIALS AND METHODS
Study design
Human NK cells are regulated by two distinctive HLA class I receptors: variable KIR that recognizes polymorphic HLA-A, HLA-B, and HLA-C and invariant CD94/NKG2A that recognizes the complex of HLA-E and a peptide cleaved from an HLA-A, HLA-B, or HLA-C leader sequence. Dimorphism at position −21 of the HLA-B leader sequence was known to give rise to functional HLA-E binding peptides with methionine and nonfunctional peptides with threonine. The objective of this study was to define the genetics of this dimorphism in the context of the world's human population and its functional impact on NK cell-mediated immunity. Population genetic analysis (using publicly available and well-curated HLA data) revealed LD between the −21 HLA-B dimorphism and other HLA-B and HLA-C dimorphisms that affect KIR recognition. Immunological studies, ex vivo phenotyping with mass cytometry, and in vitro functional assays were performed on PBMCs from a 60-donor panel, giving equal representation of the three key genotypes: M/M, M/T, and T/T. All donors were CMV-negative. The sample size was determined to be large enough to give representative sampling of donors with different HLA genotypes but of a size that was feasible for the functional assays. Randomization and blinding were not used in this observational study. Not all ex vivo experiments were run in duplicate, and functional assays were reported on the basis of mean averages. With this approach, we were able to demonstrate how the different HLA haplotype groups educate human NK cells: one by CD94/NKG2A, whereas the other by KIR.
Donors and samples
PBMCs were obtained from 60 healthy individuals and cryopreserved. These samples were the source of the analyzed NK cells. PBMCs were isolated from leukocyte reduction system (LRS) chambers through Ficoll density gradient centrifugation. LRS chambers were purchased from the Stanford Blood Center. Age and ethnicities for all donors are shown in fig. S6 .
HLA genotyping and CMV serology
Serological CMV typing and HLA-A and HLA-B genotyping of the 60 healthy individuals were determined at the Stanford Blood Center. HLA-C genotypes were determined by polymerase chain reaction-based sequence-specific oligonucleotide probe with a Luminex 100 instrument (Luminex Corp.). HLA-E genotyping was generated by polymerase chain reaction using the following primers: HLA-E*01:01F, CGAGCTGGGGCCCGACA; HLA-E*01:03F, CGAGCTGGGGCCCGACG; and HLA-E*01R, TTCCAGGTAGGCTCTCTGG. HLA-A, HLA-B, HLA-C, and HLA-E genotypes and NK cell receptor ligand assignments are shown in fig. S6 .
Functional assays
Three assays of NK cell function were performed. The first test measured the ADCC response of NK cells after challenge and culture with Raji cells coated with anti-CD20 antibody. In the second test, PBMCs were cultured overnight in the presence of IL-12, IL-15 or IL-12, and IL-15. In the third test, PBMCs previously cultured in the presence of IL-12 and/or IL-15 were further challenged and cultured with class I-deficient K562 cells. PBMCs (5 × 10 5 ) were mixed with K562 or Raji cells at a ratio of 10:1 in V-bottom 96-well plates, centrifuged at 1000 rpm for 3 min, and incubated at 37°C for 5 hours. Brefeldin A and monensin (both from BD Biosciences) were added to cultures after 1 hour. For K562 and cytokine stimulation, PBMCs cultured in complete medium and nothing else were used as negative control. For ADCC assays, Raji cells (2 × 10 6 /ml) were precoated with either rituximab (Genentech) at 10 mg/ml or murine immunoglobulin G (IgG) at 10 mg/ml for 30 min. Raji cells were washed in RPMI 1640 containing 10% heat-inactivated fetal bovine serum and then mixed with PBMCs. ADCC assays were also repeated at a single concentration of anti-human CD20 antibody (2.5 mg/ml), and cells were stained for mass cytometric analysis. We gated on all IFN-g + and CD107a + NK cells and then performed Boolean gating analysis using NKG2A, KIR2DL1, KIR2DL2/L3/S2, KIR3DL1, KIR3DL2, and LILRB1 ( Fig. 7 and fig. S9 ). We grouped NK cells into subsets on the basis of the presence or absence of CD57 followed by any KIR and LILRB1 (collectively termed KIR + ) or NKG2A.
Staining, data acquisition, and analysis PBMC samples were thawed and washed with RPMI 1640 (Corning Cellgro) containing 10% fetal bovine serum (heat-inactivated), 2 mM L-glutamine, and antibiotics [penicillin (100 U/ml) and streptomycin (100 mg/ml)] (Gibco BRL/Life Technologies) and incubated at 37°C with 5% CO 2 for 4 hours. Four million to 8 million PBMCs were stained for mass cytometric analyses, which were performed as described (24) using the 39 antibodies listed in table S1, as well as cisplatin (used as a cell viability reagent). NK cells were identified with a serial gating strategy as described ( fig. S7) (36) . The data were acquired with a CyTOF 2 instrument (Fluidigm Inc.) and analyzed using FlowJo software v9.4.8 (Tree Star Inc.) and Cytobank (Cytobank Inc.). SPADE analyses were performed on 20,000 CD94/NKG2A + NK cells from each donor using Cytobank and were restricted to a limit of 1000 phenotypes. For functional assays, NK cells were gated using anti-human antibodies (BD Biosciences): CD3 fluorescein isothiocyanate (UCHT1) and CD56 phycoerythrin (PE)-Cy7 (NCAM 16.2). NK cell function was measured by using antibodies (BD Biosciences): CD107a PE (H4A3) and IFN-g allophycocyanin (4S.B3). Samples were acquired on a BD Accuri flow cytometer (BD Biosciences).
Effects of NKG2C expression and/or CMV serostatus on expression of CD94/NKG2A Historical data comparing the frequency of NKG2A + and NKG2C + NK cells from 204 healthy donors (37) were used to corroborate our observation of the decrease in frequency and signal intensity of CD94/NKG2A staining associated with the increased number of −21M leader peptides ( fig. S11) . A cutoff value of 3% CD56 dim NK cells expressing CD94/NKG2C was used as a selection criterion for the 60 individuals in this current study.
Antibody conjugation
Antibodies were purchased from the companies specified in table S1 and labeled using Maxpar-X8 Labeling Reagent Kits (Fluidigm) according to the manufacturer's instructions and as previously reported (36).
Immunogenetic and statistical analyses
Statistical analyses were performed using Excel (Microsoft Corp.), Prism 5 (GraphPad Software Inc.), and the Open Source statistical package R (www.r-project.org). Sequence data used in the analyses of leader sequence peptides were publicly available in the Immuno Polymorphism Database (www.ebi.ac.uk/ipd/). HLA-A, HLA-B, and HLA-C genotype data used as input for haplotype analyses were publicly available in the National Center for Biotechnology Information database dbSNP (www.ncbi.nlm.nih.gov/SNP) as well as in the Allele*Frequencies (www.allelefrequencies.net). HLA-B-HLA-C and HLA-A-HLA-B haplotype frequencies and LD analyses were performed using the Genetic Analysis Package in R. Briefly, haplotypes were first inferred from genotypes using the gene counting function gc.em. The haplotype frequencies were then used as input for generating LD and c 2 statistics using the function LD22. P values for LD measurement (D′) were calculated using the c 2 test.
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